Loading organizations...

§ Private Profile · Boston, MA, USA
Biotech firm developing small molecule drugs targeting SLC transporters for inflammatory, autoimmune, cancer, and neurological diseases.
Jnana Therapeutics is a Boston, Massachusetts-based biotechnology company developing small molecule drugs that target the solute carrier (SLC) family of transporters. Their proprietary platform focuses on discovering therapies across this underexplored protein class for various diseases, including inflammatory bowel disease, monogenic disorders, cancer, and autoimmune conditions. The company has raised over $200 million in private funding, including a $107 million Series C in 2022, and operates with approximately 18-25 employees. Key investors include Polaris Partners, Avalon Ventures, and Versant Ventures, with strategic partners like Roche, Neurocrine Biosciences, AbbVie Ventures, and Pfizer. Jnana Therapeutics was founded in 2017 by Stuart Schreiber, Ramnik Xavier, Joanne Kotz, and Joel Barrish. Its business model centers on venture capital-funded biotech with revenue from partnerships and upfront payments.
Jnana Therapeutics has raised $210.0M across 3 funding rounds.
Jnana Therapeutics has raised $210.0M in total across 3 funding rounds.
Jnana Therapeutics has raised $210.0M across 3 funding rounds. Most recently, it raised $110.0M Series C in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $110M Series C | RON Renaud | ARCH Venture Partners, Avalon Ventures, Bison Ventures, Polaris Partners, Samsara BioCapital, SoftBank Investment Advisers, Versant Ventures, Polaris Partners, RA Capital Management | Announced |
| Aug 18, 2021 | $50M Series B | Matthew Hammond | AbbVie Ventures, Avalon Ventures, Polaris Partners, Versant Ventures | Announced |
| Dec 1, 2017 | $50M Series A | — | ARCH Venture Partners, Avalon Ventures, Bison Ventures, Polaris Partners, RA Capital, Samsara BioCapital, SoftBank Investment Advisers, Versant Ventures, AbbVie Ventures, Pfizer R&D Innovate, Amir Nashat | Announced |
Jnana Therapeutics is a clinical-stage biotechnology company developing first- and best-in-class small molecule therapies for diseases with high unmet needs, including rare diseases like phenylketonuria (PKU), immune-mediated diseases, and cancer.[1][2][3][5] It leverages its proprietary RAPID chemoproteomics platform to target hard-to-drug proteins, particularly the solute carrier (SLC) family of metabolite transporters, unlocking novel binding sites for drug discovery.[2][4][5][6] The company serves patients lacking effective treatments by advancing programs like JNT-517, an oral therapy blocking phenylalanine reabsorption in PKU kidneys, with strong growth momentum from a $107 million raise to fund clinical proof-of-concept and pipeline expansion.[5][7]
Headquartered in Boston and backed by leading life science investors like Bain Capital Life Sciences, Jnana focuses on systematic, efficient drug discovery to outpace conventional methods.[1][2][6]
Jnana Therapeutics was co-founded by Joanne Kotz, Ph.D. (CEO and President) and Joel C. Barrish, Ph.D. (President and CSO), world-renowned scientists aiming to pioneer the first platform targeting SLC transporters as a therapeutic class.[2][4][5] The idea emerged from recognizing SLCs—the cell's "metabolic gates"—as understudied, well-validated targets previously inaccessible to small molecule drugs, addressed via the innovative RAPID platform combining chemoproteomics with genetic screens in primary human immune cells.[2][3][4][6]
Early traction included building a pipeline for rare diseases, autoimmune conditions, and cancer, culminating in the 2022 $107 million financing to advance the lead PKU program (JNT-517) toward clinical POC and FDA Rare Pediatric Disease Designation.[5][7] Pivotal moments feature board expansions with biotech veterans like Stuart and Brian, plus a Scientific Advisory Board of academic and industry experts to guide SLC-focused innovation.[4]
Jnana rides the chemoproteomics wave, transforming drug discovery by accessing previously intractable targets amid rising demand for precision therapies in rare diseases and immunology.[2][6] Timing aligns with advances in proteomics tech and investor focus on platforms de-risking "undruggable" proteins, fueled by market forces like aging populations, unmet rare disease needs, and post-pandemic biotech funding recovery.[1][5] By unlocking SLCs, Jnana influences the ecosystem, inspiring SLC-targeted research, partnering opportunities, and faster clinical paths (e.g., FDA designations), potentially reshaping metabolic and immune disease treatment paradigms.[3][4][7]
Jnana is poised to deliver clinical data from its PKU POC study, potentially validating RAPID and SLCs as a breakthrough modality, while expanding immunology and oncology pipelines.[5][6][7] Trends like AI-enhanced proteomics and oral small molecule dominance will accelerate its trajectory, with influence growing through partnerships, further funding, and first approvals in underserved areas. As a Bain-backed leader in chemoproteomics, Jnana exemplifies how platform innovation unlocks therapeutic potential, returning to its core mission of first/best-in-class medicines for waiting patients.[1][6]
Jnana Therapeutics has raised $210.0M in total across 3 funding rounds.
Jnana Therapeutics's investors include Ron Renaud, ARCH Venture Partners, Avalon Ventures, Bison Ventures, Polaris Partners, Samsara BioCapital, SoftBank Investment Advisers, Versant Ventures, RA Capital Management, Matthew Hammond, AbbVie Ventures, RA Capital.